Guizhou Valid Pharmaceutical Co (Valid Pharmaceutical) is striving for a new development track through the process of industrial transformation and intelligent upgrading, transitioning from its prior model of "experience brewing" to "precise smart manufacturing", according to An Hai, General Manager of Valid Pharmaceutical.
Established in 1996, this comprehensive pharmaceutical manufacturing enterprise is based in the Guiyang National High-tech Industrial Development Zone, where it integrates R&D, production, sales, and services.
Currently, the company has 13 intelligent, digital, and automated extraction production lines, and five intelligent, digital, and informational production lines dedicated to the production of various syrups, soft capsules, ointments, and pills. It also uses a range of advanced "smart control" equipment made in China.
An said that, unlike the traditional allocation of a company's workforce, the new extraction workshop only requires eight personnel to conduct real-time monitoring, inspection, and operations. This represents one-eighth of its previous workforce in this area, significantly reducing labor costs.
Meanwhile, with the real-time feedback of data from smart panels and other advanced devices, the rate of human error in manual operations has been greatly reduced.
Since the beginning of this year, there have been no accidents caused by human error in the production workshop, whereas, in previous years, such mishaps accounted for at least 5 percent of all accidents.
With the continuous debugging and optimization of its production lines, the output of Valid Pharmaceuticals' main products has greatly increased.
"The complete dataization of our production process has reduced the company's overall costs by approximately 15 percent, while efficiency has increased by nearly 70 percent," An said.
The company has an annual production capacity of 10 million bottles of syrup, 500 million soft capsules, 3 million bottles of ointments, 1 million bottles of decoctions, 1 million hard capsules, and 300 million pills.
Its annual sales revenue has reached 600 million yuan ($85.59 million), highlighting its business scale.